| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1527-1531.)
© 2005 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
From the Divisions of Clinical Pharmacology (D.D., T.Y., D.M.R.) and Cardiovascular Medicine (D.D., K.C., D.M.R.), Vanderbilt University School of Medicine, Nashville, Tenn, and Cardiology Department (A.A.M.W.), Academic Medical Center, Amsterdam, the Netherlands.
Reprint requests to Dawood Darbar, MD, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Room 383, Preston Research Bldg, Nashville, TN 37232-6602. E-mail dawood.darbar{at}vanderbilt.edu
Received March 10, 2005; revision received June 7, 2005; accepted June 21, 2005.
Background The characteristic ECG pattern of ST-segment elevation in V1 and V2 in the Brugada syndrome is dynamic; it is often intermittently present in affected individuals and can be unmasked by sodium channel blockers, including antiarrhythmic drugs and tricyclic antidepressants. We report here 2 patients who developed the Brugada ECG pattern after administration of lithium, a commonly used drug not previously reported to block cardiac sodium channels.
Methods and Results Lithium induced transient ST-segment elevation (type 1 Brugada pattern) in right precordial leads at therapeutic concentrations in 2 patients with bipolar disorder. Lithium withdrawal in the patients resulted in reversion to type 2 or 3 Brugada patterns or resolution of ST-T abnormalities. In Chinese hamster ovary cells transfected with SCN5A, which encodes the cardiac sodium channel, lithium chloride caused concentration-dependent block of peak INa at levels well below the therapeutic range (IC50 of 6.8±0.4 µmol/L).
Conclusions The widely used drug lithium is a potent blocker of cardiac sodium channels and may unmask patients with the Brugada syndrome.
Key Words: Brugada syndrome lithium drugs genetics ion channels
Related Article:
Circulation 2005 112: 1519.
This article has been cited by other articles:
![]() |
Y. G. Yap, E. R. Behr, and A. J. Camm Drug-induced Brugada syndrome Europace, August 1, 2009; 11(8): 989 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. LASKE, S. R. SOEKADAR, R. LASZLO, and C. PLEWNIA Brugada Syndrome in a Patient Treated With Lithium Am J Psychiatry, September 1, 2007; 164(9): 1440 - 1441. [Full Text] [PDF] |
||||
![]() |
C. Veltmann, R. Schimpf, C. Echternach, L. Eckardt, J. Kuschyk, F. Streitner, S. Spehl, M. Borggrefe, and C. Wolpert A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification Eur. Heart J., November 1, 2006; 27(21): 2544 - 2552. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Keller, H. Huang, J. Zhao, R. Frank, V. Suarez, E. Delacretaz, M. Brink, S. Osswald, N. Schwick, and M. Chahine A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation Cardiovasc Res, June 1, 2006; 70(3): 521 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. R. Josephson, W. J. Lederer, H. A. Hartmann, D. Darbar, T. Yang, D. M. Roden, K. Churchwell, and A. A.M. Wilde Letter Regarding Article by Darbar et al, "Unmasking of Brugada Syndrome by Lithium" Circulation, March 14, 2006; 113(10): e408 - e408. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |